IL-10, a soluble cytokine produced by macrophages and regulatory T cells, provides a potential alternative to conventional anti-inflammatory treatments for atherosclerosis, although effective delivery of IL-10 that avoids off-target effects remains a significant challenge. The gene discussed is IL10; the disease is atherosclerosis.